报告题目：Enhancer reprogramming of tumor immune evasion for combination immunotherapy

报 告 人：Alfred Sze-Lok Cheng

　　　　　Associate Professor

　　　　　Deputy Chief of Cancer Biology and Experimental Therapeutics Theme 
　　　　　School of Biomedical Sciences

　　　　　Faculty of Medicine , The Chinese University of Hong Kong

报告时间：2019年7月10日（周三）下午2:30

报告地点：金沙8888js官方一楼中厅

报告人简介：

　　Understanding of cancer epigenome provides new opportunities to rewire transcriptional programs that drive hallmark tumor traits. Transcriptional enhancers are distal regulatory elements that drive lineage-specific gene expressions. Genetic and epigenetic alterations of these non-coding sequences have emerged as common molecular traits of various human cancers. Recent high-dimensional omics studies in various cancers including hepatocellular carcinoma (HCC)have emphasized on much importance for the strong immunosuppressive tumor microenvironment that counteracts the activation and infiltration of cytotoxic T lymphocytes into the tumor. In this talk, Dr. Cheng hence intend to describe their investigative scope from HCC cell epigenetics to enhancer regulation of tumor immune evasion. Based on their discoveries, they have developed mechanism-based combination immunotherapies that are supported by pharmacological proof-of-concept using preclinical models.